CA2027592A1 - Preparations pharmaceutiques solides de la forme active de la vitamine d_ a stabilite amelioree - Google Patents

Preparations pharmaceutiques solides de la forme active de la vitamine d_ a stabilite amelioree

Info

Publication number
CA2027592A1
CA2027592A1 CA2027592A CA2027592A CA2027592A1 CA 2027592 A1 CA2027592 A1 CA 2027592A1 CA 2027592 A CA2027592 A CA 2027592A CA 2027592 A CA2027592 A CA 2027592A CA 2027592 A1 CA2027592 A1 CA 2027592A1
Authority
CA
Canada
Prior art keywords
vitamin
active form
improved stability
pharmaceutical preparations
solid pharmaceutical
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA2027592A
Other languages
English (en)
Other versions
CA2027592C (fr
Inventor
Yuji Makino
Yoshiki Suzuki
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Teijin Ltd
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2027592A1 publication Critical patent/CA2027592A1/fr
Application granted granted Critical
Publication of CA2027592C publication Critical patent/CA2027592C/fr
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/59Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12Carboxylic acids; Salts or anhydrides thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A61K9/1676Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
CA002027592A 1989-03-01 1990-02-28 Preparations pharmaceutiques solides de la forme active de la vitamine d_ a stabilite amelioree Expired - Fee Related CA2027592C (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP1-46571 1989-03-01
JP1046571A JP2525478B2 (ja) 1989-03-01 1989-03-01 安定性の改良された活性型ビタミンd▲下3▼類固型製剤

Publications (2)

Publication Number Publication Date
CA2027592A1 true CA2027592A1 (fr) 1990-09-02
CA2027592C CA2027592C (fr) 1996-11-26

Family

ID=12751003

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002027592A Expired - Fee Related CA2027592C (fr) 1989-03-01 1990-02-28 Preparations pharmaceutiques solides de la forme active de la vitamine d_ a stabilite amelioree

Country Status (10)

Country Link
US (1) US5158944A (fr)
EP (1) EP0413828B1 (fr)
JP (1) JP2525478B2 (fr)
KR (2) KR930010621B1 (fr)
AT (1) ATE136782T1 (fr)
CA (1) CA2027592C (fr)
DE (1) DE69026555T2 (fr)
DK (1) DK0413828T3 (fr)
ES (1) ES2085905T3 (fr)
WO (1) WO1990009796A1 (fr)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH02240024A (ja) * 1989-03-13 1990-09-25 Ss Pharmaceut Co Ltd 活性型ビタミンd↓3類製剤用組成物
JP2845342B2 (ja) * 1990-04-28 1999-01-13 大正製薬株式会社 ビタミンd▲下3▼誘導体含有固形製剤組成物
CA2061520C (fr) * 1991-03-27 2003-04-22 Lawrence J. Daher Systeme de delivrance accelerant l'effet et accroissant la puissance
CA2065603C (fr) * 1991-04-09 2007-04-03 Hiroki Itoh Preparation de vitamine d stabilisee
US6096342A (en) 1997-03-12 2000-08-01 The Procter & Gamble Company Dosage forms of risedronate
CA2122479C (fr) * 1991-11-22 1998-08-25 Richard John Dansereau Compositions de risedronate a liberation retardee
AU3095492A (en) * 1991-12-11 1993-07-19 Central Glass Co., Ltd. 24,25-dihydroxyvitamin D3 derivative
IL103224A (en) * 1992-09-18 1998-08-16 Teva Pharma Stabilized pharmaceutical compositions containing derivatives of vitamins d2 and d3
US6406714B1 (en) 1992-12-02 2002-06-18 Merck & Co., Inc. Dry mix formulation for bisphosphonic acids
US5358941A (en) * 1992-12-02 1994-10-25 Merck & Co., Inc. Dry mix formulation for bisphosphonic acids with lactose
US6103709A (en) * 1993-12-23 2000-08-15 The Regents Of The University Of California Therapeutically effective 1α,25-dihydroxyvitamin D3 analogs and methods for treatment of vitamin D diseases
FR2724844B1 (fr) * 1994-09-23 1997-01-24 Innothera Lab Sa Association therapeutique vitamino-calcique, son procede d'obtention et son utilisation
US6716454B2 (en) 1994-09-23 2004-04-06 Laboratorie Innothera, Société Anonyme Therapeutic combination of vitamin and calcium in unitary galenic tablet form, a method of obtaining it, and the use thereof
US5698222A (en) * 1995-04-07 1997-12-16 Abbott Laboratories Calcium supplement
US6395770B1 (en) 1995-10-26 2002-05-28 Baker Norton Pharmaceuticals, Inc. Method and compositions for administering taxanes orally to human patients
US6245805B1 (en) 1995-10-26 2001-06-12 Baker Norton Pharmaceuticals, Inc. Method, compositions and kits for increasing the oral bioavailability of pharmaceutical agents
AT408416B (de) * 1996-07-19 2001-11-26 Norbert Fuchs Pharmazeutische bzw. diätetische zusammensetzungen
FI120290B (fi) * 1996-12-30 2009-09-15 Mirador Res Oy Ltd Menetelmä, jonka avulla voidaan valmistaa sellaisia mausteseos-, ruoan ainesosa- ja elintarvikekoostumuksia, jotka alentavat seerumin kolesterolia
DE19710054A1 (de) * 1997-03-12 1998-09-17 Merck Patent Gmbh Pharmazeutische Zubereitung
AR024462A1 (es) 1999-07-01 2002-10-02 Merck & Co Inc Tabletas farmaceuticas
CA2425367A1 (fr) * 2000-08-30 2003-04-07 Chugai Seiyaku Kabushiki Kaisha Formulations d'oct
KR100688618B1 (ko) * 2001-09-12 2007-03-09 주식회사 유유 비타민 d 경구투여용 서방성 약제 조성물
HUP0501186A2 (en) * 2001-12-03 2006-05-29 Novacea Pharmaceutical compositions comprising active vitamin d compounds
US20040058895A1 (en) * 2002-09-18 2004-03-25 Bone Care International, Inc. Multi-use vessels for vitamin D formulations
US7148211B2 (en) * 2002-09-18 2006-12-12 Genzyme Corporation Formulation for lipophilic agents
US20040053895A1 (en) * 2002-09-18 2004-03-18 Bone Care International, Inc. Multi-use vessels for vitamin D formulations
US20060189586A1 (en) * 2003-06-11 2006-08-24 Cleland Jeffrey L Pharmaceutical compositions comprising active vitamin D compounds
CA2882048C (fr) 2006-02-03 2020-03-24 Proventiv Therapeutics, Llc Traitement de l'insuffisance et de la deficience de vitamine d avec de la 25-hydroxyvitamine d2 et de la 25-hydroxyvitamine d3
PL2679228T3 (pl) 2006-06-21 2018-07-31 Opko Ireland Global Holdings, Ltd. Terapia z użyciem środka do uzupełniania witaminy D i środka do zastępowania hormonami witaminy D
ES2403107T3 (es) 2007-04-25 2013-05-14 Cytochroma Inc. Método de tratamiento de insuficiencia y deficiencia de vitamina D
EP3542792B1 (fr) 2007-04-25 2023-06-28 EirGen Pharma Ltd. Libération contrôlée de 25-hydroxyvitamine d
CA2713765A1 (fr) * 2008-02-06 2009-08-13 Innov'ia Composition pulverulente et son procede de preparation
HUE048464T2 (hu) 2010-03-29 2020-07-28 Opko Ireland Global Holdings Ltd Módszerek és készítmények mellékpajzsmirigy szintjének csökkentésére
EP2468265A3 (fr) * 2010-12-04 2013-01-02 DEEF Pharmaceutical Industries Co. Préparations homogènes contenant de la vitamine D
KR101847947B1 (ko) 2013-03-15 2018-05-28 옵코 아이피 홀딩스 Ⅱ 인코포레이티드 안정화되고 변형된 비타민 d 방출 제형
CA2957240A1 (fr) 2014-08-07 2016-02-11 Opko Ireland Global Holdings, Ltd. Therapie d'appoint avec de la 25-hydroxyvitamine d
JP7034595B2 (ja) * 2016-03-23 2022-03-14 株式会社ファンケル ビタミンd3安定化組成物
JP7032322B2 (ja) 2016-03-28 2022-03-08 オプコ アイルランド グローバル ホールディングス リミテッド ビタミンd治療法
TWI784997B (zh) * 2016-12-28 2022-12-01 日商中外製藥股份有限公司 包含ed-71的固體分散體與油分散體的醫藥組合物
US11638439B2 (en) * 2018-05-21 2023-05-02 Agthia Vitamin D-fortified water and method of manufacturing thereof
KR20210024566A (ko) 2018-06-27 2021-03-05 추가이 세이야쿠 가부시키가이샤 유지 중에 ed-71 및 그의 에폭시체를 포함하는 유분 분산체를 포함하는 의약 조성물

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2195596A (en) * 1936-11-07 1940-04-02 Squibb & Sons Inc Protected-vitamin-containing tablet
US2691619A (en) * 1951-09-18 1954-10-12 Pfizer & Co C Fat-soluble vitamin-containing products and process therefor
DE1492034A1 (de) * 1965-05-18 1969-02-20 Merck Ag E Verfahren zur Herstellung fester haltbarer Zubereitungen von empfindlichen,in Wasser schwer loeslichen Wirkstoffen,vorzugsweise Arzneimitteln
US3901928A (en) * 1973-01-10 1975-08-26 Robert Henry Hesse 1' ,3' -dihydroxy steroid-5-enes method of preparing same and their use for preparing 1' -hydroxy-25-hydrogen vitamin d compounds
JPS5418330B2 (fr) * 1973-03-16 1979-07-06
DE2400819C2 (de) * 1974-01-09 1982-04-22 Bayer Ag, 5090 Leverkusen Verfahren zur Herstellung fester Zubereitungen von schwerlöslichen Arzneimittelwirkstoffen in feinster Verteilung
JPS51128417A (en) * 1975-04-28 1976-11-09 Teijin Ltd A method for stabilizing active vitamin d3 derivatives
US4069321A (en) * 1975-10-14 1978-01-17 Merck & Co., Inc. Blocked cholecalciferol and dihydrotachysterol 3 derivatives
JPS5740415A (en) * 1980-08-25 1982-03-06 Teijin Ltd Novel active type vitamin d3 derivative composition
JPS5740414A (en) * 1980-08-25 1982-03-06 Teijin Ltd Novel active type vitamin d3 derivative composition
JPS5740461A (en) * 1980-08-25 1982-03-06 Teijin Ltd Novel activated vitamin d3 derivative composition
US4308264A (en) * 1981-01-28 1981-12-29 Abbott Laboratories Stabilized, dilute aqueous preparation of 1α,25-dihydroxycholecalciferol for neonatal administration
US4652405A (en) * 1981-08-28 1987-03-24 Hoffman-La Roche Inc. Synthesis of 1α,25-dihydroxy-24R-fluorocholecalciferol and 1α,25-dihydroxy-24S-fluorocholecalciferol
US4617297A (en) * 1982-02-12 1986-10-14 Hoffmann-La Roche Inc. Method of treating disease states by the administration of 1α,25,26-trihydroxycholecalciferol
JPS58206533A (ja) * 1982-05-27 1983-12-01 Teijin Ltd 活性型ビタミンd↓3誘導体組成物及びそれを活性成分とする薬剤
JPS59155309A (ja) * 1983-02-22 1984-09-04 Teijin Ltd 活性型ビタミンd↓3類組成物
JPS6141351A (ja) * 1984-07-31 1986-02-27 日産自動車株式会社 空気噴射式織機の緯糸端部処理装置
JPS6144860A (ja) * 1984-08-10 1986-03-04 Taisho Pharmaceut Co Ltd 1α.25−ジヒドロキシ−26.27−ジメチルビタミンD↓3
US4613594A (en) * 1984-11-16 1986-09-23 Hoffmann-La Roche Inc. Fluorinated vitamin D3 compounds
JPS6217A (ja) * 1985-02-14 1987-01-06 Chugai Pharmaceut Co Ltd 安定な活性型ビタミンd3類製剤
JPS6251948A (ja) * 1985-07-23 1987-03-06 廖 阿亮 デコレーション用プレザープとその製造方法
JPH0635442B2 (ja) * 1985-08-28 1994-05-11 住友精化株式会社 チオカルバメ−ト誘導体の製造法
JPS62149619A (ja) * 1985-09-05 1987-07-03 Teijin Ltd 活性型ビタミンd3類注射用組成物
JPS6346728A (ja) * 1986-08-15 1988-02-27 Hitachi Electronics Eng Co Ltd ランプ電源制御方式および制御回路
JPS6425723A (en) * 1988-07-07 1989-01-27 Teijin Ltd Production of active type vitamin d3 composition

Also Published As

Publication number Publication date
KR930010621B1 (ko) 1993-11-02
ES2085905T3 (es) 1996-06-16
US5158944A (en) 1992-10-27
DE69026555D1 (de) 1996-05-23
DK0413828T3 (da) 1996-05-13
EP0413828A4 (en) 1991-10-30
JP2525478B2 (ja) 1996-08-21
KR920700036A (ko) 1992-02-19
EP0413828B1 (fr) 1996-04-17
EP0413828A1 (fr) 1991-02-27
WO1990009796A1 (fr) 1990-09-07
ATE136782T1 (de) 1996-05-15
CA2027592C (fr) 1996-11-26
JPH02229115A (ja) 1990-09-11
DE69026555T2 (de) 1996-09-19

Similar Documents

Publication Publication Date Title
CA2027592A1 (fr) Preparations pharmaceutiques solides de la forme active de la vitamine d_ a stabilite amelioree
IE881916L (en) Press-coated dihydropyridine tablets
CA2180816A1 (fr) 6-dimethylaminomethyl-1-phenylcyclohexanes, principes actifs en pharmacie
CA2071623A1 (fr) Composition a base de cyclodextrine
ATE109145T1 (de) Heterozyklische acylaminothiazolderivate, ihre herstellung und diese enthaltende pharmazeutische zubereitungen.
MY101847A (en) Composition for solid pharmaceutical preparations of active vitamins d 3 and process for preparation thereof.
EP0348808A3 (fr) Formulations pharmaceutiques et procédé pour leur préparation
CA2004598A1 (fr) Aerosols medicinaux
ATE37028T1 (de) Cephalosporinverbindungen, ihre herstellung, pharmazeutische praeparate und eingangsprodukte.
CA2152795A1 (fr) Excipient de glucomannane de konjac a liberation-retard et rapidement utilisable
AU587281B2 (en) Slow-release pharmaceutical agent
HUT61031A (en) Process for producing chemically modified, stable haemoglobin substituting for non-immunogehic red blood cell, and pharmaceutical compositions comprising same as active ingredient
EP0221041A3 (fr) Dérivés de benzimidazole, leur préparation et leur application comme médicaments
SE8504945L (sv) Farmaceutiska kompositioner innehallande antracyklinglykosider
CA2172616A1 (fr) Tropyl 7-azaindol-3-ylcarboxamides, antitussifs
AU3091489A (en) Piperazine derivative or its salt, process for producing the same and pharmaceutical composition comprising the same as active ingredient
IL84446A0 (en) 3-pyrrolidinylthio-1-azabicyclo-(3.2.0)hept-2-ene-2-carboxylic acid derivatives,processes for the preparation thereof and pharmaceutical compositions containing the same
CA2065603A1 (fr) Preparation de vitamine d stabilisee
AU8096591A (en) Composition for solid pharmaceutical preparations containing active vitamins d3 and process for preparation thereof
IE781032L (en) Pharmaceutical compositions
AU8315287A (en) New alkanesulfonanilide and alkylaminosulfonanilide derivatives, processes for their preparation and pharmaceutical compositions comprising the same
AU7547787A (en) Dibenz(b,e)oxepin derivative and pharmaceutical containing the same as active ingredient
CA2063273A1 (fr) Surfactants pulmonaires et methodes
GB2021409A (en) Pharmaceutical composition
ATE32882T1 (de) Phenylnonatetraensaeurederivate, ihre herstellung und pharmazeutische praeparate mit diesen derivaten.

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed